Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Juniper Pharmaceuticals Inc (NASDAQ: JNP) acted responsibly on behalf of investors’ profitability in the planned sale to Catalent Inc.

On July 3, 2018, Juniper Pharmaceuticals Inc (NASDAQ: JNP) and Catalent Inc announced that they had entered into a merger agreement. Under the terms of the merger agreement, Catalent will offer Juniper shareholders $11.50 per share in cash for all outstanding shares.    

Based in Boston, Massachusetts, and founded in 1986 Juniper Pharmaceuticals Inc focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health.

The investigation is looking to uncover whether Juniper Pharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $20.00 per share.

If you purchased Juniper Pharmaceuticals Inc (NASDAQ: JNP) prior to July 3, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185